ArticleAnnals of coloproctology2021
Effect of Adjuvant Chemotherapy on Elderly Stage II High-Risk Colorectal Cancer Patients.
Article in Annals of coloproctology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Long-term outcomes in elderly colorectal cancer patients with presarcopenia: a single center retrospective cohort study.BMC geriatrics · 2026Article
- Oncologic outcomes of multivisceral resection for locally advanced colorectal cancer: a single-center retrospective cohort study.BMC surgery · 2025Article
- Predicting venous thromboembolism and determining appropriate prophylaxis in elderly patients undergoing colorectal cancer surgery with Enhanced Recovery After Surgery (ERAS) using the adjusted Caprini score.Annals of coloproctology · 2025Article
- Oncologic outcomes and associated factors of colon cancer patients aged 70 years and older.Annals of coloproctology · 2025Article
- Tumor aggression-defense index-a novel indicator to predicts recurrence and survival in stage II-III colorectal cancer.Journal of translational medicine · 2025Article
- A Prognostic Model Based on the Log Odds Ratio of Positive Lymph Nodes Predicts Prognosis of Patients with Rectal Cancer.Journal of gastrointestinal cancer · 2024Article
- Advances in the Treatment of Colorectal Cancer with Peritoneal Metastases: A Focus on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.Ewha medical journal · 2023Review
- Clinical implication of tissue carcinoembryonic antigen expression in association with serum carcinoembryonic antigen in colorectal cancer.Scientific reports · 2023Article
- Is the oncological impact of vascular invasion more important in right colon cancer?Journal of minimally invasive surgery · 2022Article
- Article
- Oncologic outcomes in elderly patients who underwent hysterectomy for endometrial cancer: a multi-institutional survey in Kinki District, Japan.International journal of clinical oncology · 2022Article
- Risk factors for recurrence in elderly patients with stage II colorectal cancer: a multicenter retrospective study.BMC cancer · 2022Article
- Effects of the Enhanced Recovery After Surgery (ERAS) Program for Colorectal Cancer Patients Undergoing Laparoscopic Surgery.Clinical nutrition research · 2022Article
- Epidemiology, Risk Factors, and Prevention of Colorectal Cancer-An English Version.Journal of the anus, rectum and colon · 2022Review
- Molecular Analyses in Peritoneal Metastasis from Colorectal Cancer: A Review-An English Version.Journal of the anus, rectum and colon · 2022Review
- Elderly High-Risk Stage II Colorectal Cancer Patients: Candidates for Improving Outcome?Annals of coloproctology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAdjuvant chemotherapy (AC) is recommended for patients with stage II colorectal cancer with adverse features. However, the effect of adjuvant treatment in elderly patients with high-risk stage II colorectal cancer remains controversial. This study aimed to investigate the oncologic outcomes in elderly high-risk stage II colorectal cancer patients who underwent curative resection with or without AC.
methodsPatients aged over 70 years having stage II colorectal adenocarcinoma with at least 1 adverse feature who underwent radical surgery between 2008 and 2017 at a single center were included. We compared recurrence-free survival (RFS) and overall survival (OS) between patients who received more than 80% of the planned AC cycle (the AC+ group) and those who did not receive it (the AC- group).
resultsThe AC+ and AC- group contained 46 patients and 50 patients, respectively. The log-rank test revealed no significant intergroup differences in RFS (P=0.083) and OS (P=0.122). In the subgroup of 27 patients with more than 2 adverse features, the AC+ group (n=16) showed better RFS (P=0.006) and OS (P=0.025) than the AC- group. In this subgroup, AC was the only significant factor affecting RFS in the multivariate analysis (P=0.023). AC was significantly associated with OS (P=0.033) in the univariate analysis, but not in the multivariate analysis (P=0.332).
conclusionAmong elderly patients with stage II high-risk colorectal cancer, the AC+ group did not show better RFS or OS than the AC- group. However, selected patients with more than 2 adverse features might benefit from AC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.